Yarrow Bioscience (YARW) EBT (2017 - 2026)
Yarrow Bioscience's (YARW) quarterly EBT came in at -$3.6 million in Q1 2026, up 58.33% YoY from -$2.3 million in Q1 2025, and up 37.62% on a QoQ basis from -$5.7 million in Q2 2025.
Yarrow Bioscience (YARW) EBT (2017 - 2026) Analysis & Trends
Yarrow Bioscience (YARW) has 10 years of EBT data on file, last reported at -$3.6 million in Q1 2026.
- Quarterly EBT rose 58.33% year-over-year to -$3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$29.9 million (up 28.98% YoY) and the FY2025 annual result came in at -$26.7 million, up 32.84% from the prior year.
- EBT climbed to -$3.6 million in Q1 2026, from -$5.7 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$3.6 million in Q1 2026 to a low of -$12.2 million in Q3 2024.
- A 5-year average of -$8.0 million and a median of -$8.2 million in 2022 frame the typical range for EBT.
- Annual changes were most pronounced in 2024 — EBT tumbled 100.25% — and 2026, when it jumped 58.33%.
- Tracing YARW's EBT over 5 years: stood at -$7.7 million in 2022, then climbed by 20.6% to -$6.2 million in 2023, then tumbled by 95.22% to -$12.0 million in 2024, then jumped by 52.15% to -$5.7 million in 2025, then soared by 37.62% to -$3.6 million in 2026.
- The last three EBT figures came in at -$3.6 million (Q1 2026), -$5.7 million (Q2 2025), and -$8.6 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Yarrow Bioscience | 32.54 Mn | 9.62 Mn | - | -2.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.90 Mn |
| Mar 31, 2026 | -3.59 Mn |
| Jun 30, 2025 | -5.75 Mn |
| Mar 31, 2025 | -8.60 Mn |
| Dec 31, 2024 | -12.01 Mn |
| Sep 30, 2024 | -12.16 Mn |
| Jun 30, 2024 | -9.40 Mn |
| Mar 31, 2024 | -6.24 Mn |
| Dec 31, 2023 | -6.15 Mn |
| Sep 30, 2023 | -6.07 Mn |
| Jun 30, 2023 | -10.04 Mn |
| Mar 31, 2023 | -5.61 Mn |
| Dec 31, 2022 | -7.75 Mn |
| Sep 30, 2022 | -9.26 Mn |
| Jun 30, 2022 | -8.24 Mn |
| Mar 31, 2022 | -8.69 Mn |
| Dec 31, 2021 | -8.82 Mn |
| Sep 30, 2021 | -14.28 Mn |
| Jun 30, 2021 | -10.69 Mn |
| Mar 31, 2021 | -10.88 Mn |